Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Early and accurate prognosis of Alzheimer’s disease (AD) remains limited by current biomarkers, which are often invasive, require expensive equipment, or fail to predict individual trajectories of cognitive decline.
Why it matters
This study evaluated a digital twin framework that extracts biomarkers from non-invasive EEG recordings in 459 participants with subjective cognitive decline or mild cognitive impairment over a 10-year follow-up. The digital biomarkers predicted conversion and matched or outperformed established Alzheimer disease biomarkers, and combining them with established biomarkers increased prognostic accuracy.
-
Agricultural pesticide use represents one of the most geographically patterned environmental systems, yet most prior research has focused largely on individual compounds rather than correlated exposure regimes.
Why it matters
This cross-sectional county-level analysis found that 20 of 25 pesticide exposure clusters were significantly associated with Alzheimer's disease dementia prevalence. The authors state that the findings warrant higher-resolution, longitudinal investigation, so no causal or preventive conclusion can be drawn yet.
-
Using a 2-sample Mendelian randomization (MR) approach, we evaluated MR evidence for genetically proxied effects of 10 pre-specified gut bacterial classes on type 2 diabetes mellitus (T2DM) and Alzheimer disease (AD), and assessed MR evidence for a direct genetically proxied effect of T2DM on AD.
Why it matters
This genetic analysis found no robust evidence that type 2 diabetes directly affects Alzheimer's disease risk, but it did find that higher genetically predicted Clostridia abundance was associated with lower Alzheimer's disease risk. These findings come from statistical genetic methods and do not establish that changing gut bacteria would prevent or treat Alzheimer's disease.
-
39/100
COVID‐19 increases new MCI/ADRD risk.
Why it matters
In this analysis of Medicare Advantage claims, COVID-19 infection was linked to about 1.4 times higher risk of new mild cognitive impairment or dementia and a 4 percentage point increase in 32-month incidence. Higher infection rates among Black and Hispanic beneficiaries widened disparities, which the authors say points to a need for targeted prevention and cognitive care.
-
Although β-site APP-cleaving enzyme 1 (BACE1) and secretase inhibitors did not achieve success in clinical trials because of mechanism-based toxicity and cognitive impairment, new monoclonal antibodies such as lecanemab and donanemab have shown high amyloid plaque clearance and reduced cognitive deterioration.
Why it matters
This review notes that lecanemab and donanemab clear amyloid plaques and reduce cognitive deterioration but are associated with amyloid-related imaging abnormalities, while BACE1 and secretase inhibitors failed in trials. It argues that treatment should move toward multi-target combinations and precision neuropharmacology, which remains a future direction rather than an established approach.
-
Despite advances in disease-modifying treatments, significant barriers in the evaluation and clinical management of people with early Alzheimer's disease (AD) remain.
Why it matters
This article identifies systemic and structural barriers that keep US primary care professionals from playing a larger role in detecting, diagnosing, treating and monitoring early Alzheimer's disease, and proposes solutions. It is a health-system commentary and does not itself test any treatment, cure or prevention.
-
Fourteen studies met eligibility criteria, covering populations from healthy controls to individuals with subjective cognitive decline, MCI, AD, and other dementias.
Why it matters
This review of fourteen studies found that AI-driven MEG analyses showed classification accuracies ranging from about 60% to over 80% for distinguishing diagnostic categories or predicting MCI-to-AD progression. The authors note heterogeneity across studies and state that standardized pipelines, larger multicenter cohorts, and explainable AI are needed before clinical translation.
-
All recently approved monoclonal antibodies (eg, aducanumab, lecanemab, and donanemab) for Alzheimer disease (AD) were shown to increase the risks of amyloid-related imaging abnormalities (ARIA) in randomized clinical trials, which can include brain swelling or hemorrhage.
Why it matters
This real-world evidence study was designed to evaluate the risk of amyloid-related imaging abnormalities, which can include brain swelling or hemorrhage, in patients receiving monoclonal antibodies such as aducanumab, lecanemab and donanemab compared with nonmonoclonal treatments. It also aimed to investigate health care resource utilization, including emergency department and inpatient visits, between the two groups.
-
Alzheimer disease (AD) and epilepsy are major causes of neurologic disability and are reciprocally related: epileptiform discharges, subclinical seizures, and epilepsy are more prevalent in patients with AD compared with controls; progressive cognitive impairment commonly afflicts epilepsy patients; and late-onset epilepsy patients have higher rates of new-onset dementia.
Why it matters
This review describes shared risk factors and overlapping brain, clinical, and pathological features between Alzheimer's disease and epilepsy, along with notable differences. It does not report any treatment, cure, or prevention, and the shared mechanisms remain unresolved challenges.
-
Synaptic loss in the (para)hippocampus is a major contributor to cognitive decline in Alzheimer's disease (AD), yet its regional specificity and pathological correlates remain poorly understood.
Why it matters
In postmortem brain tissue from 28 people with Alzheimer's disease and 17 controls, synaptic loss was found in the entorhinal cortex and parahippocampal gyrus, and worse cognitive performance was strongly associated with synaptic loss in several regions. This describes patterns of brain changes and does not test a treatment.
-
Residence in the most disadvantaged neighborhoods may be associated with lower amyloid pathology in cognitively impaired individuals.
Why it matters
People with cognitive impairment living in the most disadvantaged neighborhoods were less likely to have a positive amyloid PET scan by visual reading, though the result was not significant using a different amyloid measure. This suggests neighborhood disadvantage may be linked to lower amyloid pathology in this group.
-
= 0.75) of the variance in AD prevalence.
Why it matters
This artificial intelligence analysis found that racial and ethnic minority status had the highest importance value (0.848) among predictors of AD prevalence, far exceeding other features such as poor sleep. The study is about upstream predictors of AD prevalence and policy implications, not about treating, curing, or preventing Alzheimer's disease.
-
Alzheimer\\\'s disease (AD), the leading cause of dementia worldwide, affects more than 55 million individuals and gen-erates annual healthcare costs exceeding two trillion USD [14].
Why it matters
A reviewed longitudinal MRI study using 3D CNNs, T-LSTM networks, and radiomics predicted MCI-to-AD conversion with a c-index of 0.90 and time-specific AUCs of 0.96, 0.94, and 0.89 for 2-, 3-, and 5-year prediction. This is a prediction and prognostication tool, not a treatment, cure, or prevention.
-
Mixed dementia (MD), characterized by overlapping features of Alzheimer's disease (AD) and vascular dementia (VaD), represents the most prevalent form of late-life cognitive decline.
Why it matters
This review proposes oxidative stress as a shared mechanism in mixed dementia and discusses experimental approaches such as mitochondrial protection, Nrf2 activation, and stem cell-derived extracellular vesicles. It is a narrative review, so it does not show that any of these approaches treat or prevent Alzheimer's disease in patients.
-
39/100
The repeated inability of Aβ therapies to pass clinical tests in sporadic AD points to the complexity of the disease and indicates that earlier or more interventions could be necessary.
Why it matters
This describes a hypothetical therapeutic framework, not a tested treatment in people, so it does not show that CRISPR/Cas9 can treat or prevent Alzheimer's in patients. It reports that gene editing reduced amyloid and tau and improved learning and memory in animal and cell models, which is early evidence only.
-
Vascular burden influences NfL levels, particularly in amyloid‐negative individuals.
Why it matters
In this memory clinic group, plasma neurofilament light increased stepwise from those with neither amyloid nor vascular pathology to those with both, suggesting an additive effect. Regression analysis found small vessel disease score, but not amyloid status, significantly predicted neurofilament light levels, and amyloid status moderated the effect of small vessel disease.
-
39/100
We have successfully generated specific high affinity monoclonal antibodies against p -Tau217, p -Tau205, and N-terminus GFAP and have confirmed that these antibodies have the necessary specificity and sensitivity for the Simoa platform.
Why it matters
Researchers generated monoclonal antibodies against p-Tau217, p-Tau205, and N-terminus GFAP and confirmed they work on the Simoa platform. This is early laboratory work; the assays still need to be validated in a control and Alzheimer cohort before any clinical use.
-
A total of 143 patients with cognitive concerns were included who underwent a PrecivityAD2 test as part of their clinical evaluation.
Why it matters
In a very small group of 143 patients, the PrecivityAD2 blood test agreed with CSF or PET results in those who had both tests, and 34 patients were treated with lecanemab. The authors state the study is very small but support using high-accuracy blood biomarker tests to guide anti-amyloid treatment in patients with high clinical likelihood of amyloid pathology.
-
Alzheimer’s disease is the most common type of dementia, characterized by a progressive decline in cognitive function, particularly memory and impacting daily life.
Why it matters
This is a general review of Alzheimer's disease diagnosis and background, noting that the disease starts earlier in people with Down syndrome. It reports no new findings on treating, curing or preventing Alzheimer's disease.
-
Concentrations of CSF APP were significantly lower in T- compared to T+ individuals across all clinical diagnostic groups across cohorts, regardless of A± status (Figure 1).
Why it matters
This study found that low cerebrospinal fluid APP concentrations were most pronounced in p-tau negative cases clinically diagnosed with Alzheimer's disease, and that low APP combined with high p-tau was linked to the most severe cognitive and functional impairments. It concerns refining diagnosis rather than treating, curing or preventing Alzheimer's disease.
-
We observed two promising biomarkers of AD, mLOY and APR, both contribute discriminating AD and CI but differently.
Why it matters
This study examined mosaic loss of chromosome Y and the plasma Aβ42/p-tau181 ratio as possible biomarkers for Alzheimer's disease in Amish men. It is a biomarker study and does not test or demonstrate any treatment, cure or prevention.
-
For the 30 clinically-diagnosed DLB participants, 23 (77%) were SAA-positive.
Why it matters
In this small group of 30 people clinically diagnosed with dementia with Lewy bodies, 77% tested positive on a cerebrospinal fluid seed aggregation assay, and results stayed the same over 1-2 years in those retested. There were no significant differences in Alzheimer's biomarker levels between those who tested positive and negative, and one autopsy case that was negative for the assay showed Alzheimer's pathology but no Lewy body pathology, so the test's meaning for Alzheimer's disease remains unclear.
-
Biomarkers specific to AD pathology (p-tau217, GFAP) rather than peripheral inflammation had robust prognostic value in established AD.
Why it matters
In 333 patients with mild to moderate Alzheimer's disease followed for 18 months, blood markers of peripheral inflammation did not predict clinically significant progression, while biomarkers of underlying Alzheimer's pathology and neuroinflammation did. Peripheral inflammatory markers stayed stable over 18 months even as patients declined, suggesting they are not useful for tracking disease progression in established Alzheimer's disease.
-
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by memory loss, cognitive decline, and behavioral changes.
Why it matters
Current drugs for Alzheimer's disease mainly include cholinesterase inhibitors and NMDA receptor antagonists, which aim to relieve symptoms and slow disease progression. New therapeutic directions focus on disease modification by targeting amyloid and tau pathology, oxidative stress, and neuroinflammatory pathways, with advances such as monoclonal antibodies and small-molecule inhibitors possibly leading to more effective therapies.
-
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques.
Why it matters
This project describes a deep learning system that reads MRI brain images and predicts early signs of Alzheimer's, with a web interface for uploading scans. No results from testing the system on patients are reported, so it is not yet evidence that it improves diagnosis or slows the disease.
From across this topic
9 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Autophagy in alzheimer disease pathogenesis and its therapeutic values
- Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease
- Diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease: a review
- Can Telehealth Improve Access to Amyloid-Targeting Therapies for Veterans Living With Alzheimer Disease?
- Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease
- Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species
- Associations of accelerated biological ageing with incident dementia, cognitive functions and brain structure: a prospective cohort study based on UK Biobank
- CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease
- Epidemiology of Alzheimer disease